Drug name: Iron Oxide and Gold Nanoparticles

Related CSCTT Targets

CD138-/CD34- cells [ref.1]


Among the broad diversity of nanoparticles, iron oxide nanoparticles (Fe-NPs) and gold nanoparticles (Au-NPs) are the most intensively studied. Inherent merits of Fe-NP are strong magnetization and that it exhibits little to no toxicity in vivo. In the clinical area of human medicine, these particles are used as delivery vehicles for drugs, genes, and radionuclides.

Functionalized Au-NPs are promising candidates for drug delivery because of their unique dimensions, tunable functionalities on the surface, and controllable drug release.

Paclitaxel is one of the most popular chemotherapeutic agents used nowadays for treatment of breast, ovarian, and lung cancers. Being able to promote tubulin assembly into microtubules, paclitaxel brings significant impact mainly because of its mechanism of action. On the other hand, its drawbacks come from the lack of tumor specificity and low solubility in water. To overcome these barriers, many researchers planned to attach paclitaxel onto the biocompatible nanoparticles[1,2].

[1] Hwu, J. R., et al. (2009). "Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles." J Am Chem Soc 131(1): 66-68.
[2] Liu, Y., et al. (2011). "Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel." Int J Mol Sci 12(7): 4395-4413.




  • [1] Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.
    Yang, C., et al. (2013). Int J Nanomedicine 8: 1439-1449. [ 23610522 ]

Back to top